Ropes & Gray represented ImmunoGen in the deal. ImmunoGen, Inc. (Nasdaq: IMGN) announced it has entered into an exclusive collaboration with Takeda Pharmaceutical Company Limited (TSE:...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Verastem Oncology on the deal. Verastem Oncology (Nasdaq: VSTM) announced that the company has entered into a discovery and development collaboration with...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented ImmunoGen in the deal. ImmunoGen, Inc. announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem Corporation on the...
You must be a Standard 1 Year member to access this content.
Thompson Hine advises STERIS, and Ropes & Gray advises Becton, Dickinson and Company on the deal. STERIS plc (NYSE: STE) announced that the company has signed...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Ovid Therapeutics on the deal. Ovid Therapeutics announced a collaboration with Graviton Bioscience Corporation under which Ovid obtained exclusive rights to develop...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Xeris Biopharma Holdings on the deal. Xeris Biopharma Holdings announced a platform research evaluation, collaboration and option agreement with Regeneron Pharmaceuticals, Inc....
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented ImmunoGen, Inc. on the deal. ImmunoGen, Inc., a leader in the field of antibody-drug conjugates, announced a global, multi-target license and option agreement...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Amarin Corporation plc on the deal. Pharmaceutical company Amarin Corporation plc announced an agreement with CSL Seqirus for an exclusive license and distribution...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised TRexBio on the deal. TRexBio in a multi-year research collaboration and exclusive worldwide license agreement with Eli Lilly and Company to develop...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised ImmunoGen on the deal. ImmunoGen, a leader in the field of antibody-drug conjugates for cancer treatment, in a clinical collaboration with Gilead...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Xeris Biopharma on the deal. Xeris Biopharma announced a research collaboration and option agreement with Horizon Therapeutics. Under the agreement announced on November...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Cambrex on the deal. Cambrex, a global contract development manufacturing organization (CDMO) providing products and services across the entire drug lifecycle, signed a...
You must be a Standard 1 Year member to access this content.
